Search Results
Found 2 results
510(k) Data Aggregation
(93 days)
WAMPOLE LABORATORIES
The Borrelia burgdorferi IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of IgM antibodies to Borrelia burgdorferi in human serum. This ELISA should only be used for patients with signs and symptoms that are consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgdorferi and can be used to support a clinical diagnosis of Lyme disease.
The Borrelia burgdorferi IgM ELISA test is an enzyme linked immunosorbent assay to detect IgM antibodies to Borrelia burgdorferi. Purified Borrelia burgdorferi antigen is attached to a solid phase microtiter well. Pretreated test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgM is added to each well. If antibody is present it will bind to the antibody attached to the antigen on the well. After incubation the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present the substrate will undergo a color change. After an incubation period the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.
Here's an analysis of the provided information regarding the Borrelia burgdorferi IgM ELISA Test Kit, structured according to your request.
Device Name: Borrelia burgdorferi IgM ELISA Test Kit
1. Table of Acceptance Criteria and Reported Device Performance
It's important to note that the provided documents do not explicitly state "acceptance criteria" as clear pass/fail thresholds. Instead, they present performance characteristics from various studies. Based on the provided data, I have inferred what could be considered the reported performance of the device in these studies.
Acceptance Criteria (Inferred) | Reported Device Performance (Wampole Borrelia burgdorferi IgM ELISA) |
---|---|
Sensitivity (Agreement with Clinical Diagnosis) for Lyme Disease (CDC Panel) | 47.6% (20/42) when equivocals are considered 1-step positive. |
Agreement with Clinical Diagnosis for Normals (CDC Panel) | 100% (5/5) |
Agreement with Clinical Diagnosis for 1 year post-onset (CDC Panel) | 12.5% (1/8) |
2-step positive rate (ELISA pos/eq & Western Blot pos) among total tested in a real-world setting | 3.41% (6/176) |
2-step positive rate (ELISA pos/eq & Western Blot pos) among 1-step pos or eq in a real-world setting | 31.6% (6/19) |
Inter-site precision (CV) | Generally |
Ask a specific question about this device
(93 days)
WAMPOLE LABORATORIES
The Borrelia burgdorferi IgG/IgM ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative presumptive detection of total (IgG/IgM) antibodies to Borrelia burgdorferi in human serum. This ELISA should only be used for patients with signs and patients with symptoms that are consistent with Lyme disease. Equivocal or positive results should be supplemented by testing with a standardized Western blot procedure. Positive supplemental results are supportive evidence of exposure to B. burgdorferi and can be used to support a clinical diagnosis of Lyme disease.
The Borrelia burgdorferi IgG/IgM ELISA test is an enzyme linked immunosorbent assay to detect IgGM antibodies to Borrelia burgdorferi. Purified Borrelia burgdorferi antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, thev will bind to the antigen in the well. After incubation the wells are washed to remove unbound antibodv. An enzyme labeled anti-human IgG/IgM is added to each well. If antibody is present it will bind to the antibody attached to the antigen on the well. After incubation the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present the substrate will undergo a color change. After an incubation period the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.
Here's a breakdown of the acceptance criteria and study information for the Borrelia burgdorferi IgG/IgM ELISA Test Kit, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The document doesn't explicitly state formal "acceptance criteria" with specific numerical thresholds for all performance metrics. However, we can infer the desired performance and report the observed results.
Acceptance Criterion (Inferred) | Reported Device Performance | Section from Document |
---|---|---|
Clinical Sensitivity (agreement with clinical diagnosis for Lyme disease) | 71% (30/42) | Wampole B. burgdorferi IgG/IgM ELISA Result |
Clinical Specificity (agreement with negative diagnosis for normals) | 100% (5/5) | Table 1 The CDC Lyme Disease Serum Panel Stratified by Time After Onset. |
Agreement with Predicate Device (Lyme STAT) post 2-step testing | Wampole: 4% (1.0%-6.9%) (7/176) | |
Lyme Stat: 2.8% (0.3%-5.3%) (5/176) | Study 2: Table 2 | |
Precision (Intersite CV) | Generally |
Ask a specific question about this device
Page 1 of 1